Emicizumab for the treatment of acquired hemophilia A

Emicizumab for the treatment of acquired hemophilia A | Blood

Emicizumab is a bispecific, FVIII-mimetic therapeutic antibody that reduced the annualized bleeding rates in congenital hemophiliacs.

Emicizumab for the treatment of acquired hemophilia A - PubMed

Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII).

The role of emicizumab in acquired hemophilia A - ASH Publications

Emicizumab is a factor VIII (FVIII) mimetic approved for bleeding prophylaxis in congenital hemophilia A with and without FVIII inhibitors.

Emicizumab for the treatment of acquired hemophilia A - PubMed

Our observations suggest emicizumab can facilitate haemostasis for AHA patients and be combined with safer, lower-intensity ...

A prospective, multicenter, open-label phase III study of emicizumab ...

The benefit-risk profile of emicizumab prophylaxis for acquired hemophilia A (AHA) is unknown. ... Emicizumab with a newly developed dosing ...

Emicizumab as first-line therapy in acquired hemophilia A

Numerous arguments from recent clinical experiences suggest positioning emicizumab as a first-line treatment for AHA. This strategy has the potential to reduce ...

Emicizumab for the treatment of acquired hemophilia A ...

Conclusion. Our observations suggest emicizumab can facilitate haemostasis for AHA patients and be combined with safer, lower-intensity ...

Emicizumab: A Promising Option for Hemostatic Control in Acquired ...

Emicizumab: A Promising Option for Hemostatic Control in Acquired Hemophilia A ... Emicizumab offers an excellent hemostatic option for control of ...

Emicizumab for the treatment of acquired hemophilia A - ScienceDirect

Emicizumab is a bispecific, FVIII-mimetic therapeutic antibody that reduced the annualized bleeding rates in congenital hemophiliacs.

Emicizumab for the Treatment of Acquired Hemophilia A

Abstract. Background Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation factor VIII ...

Emicizumab in acquired haemophilia A: about two clinical cases ...

Emicizumab, a bispecific antibody that mimics the action of FVIII, has proven effective in managing patients with congenital haemophilia, with or without ...

Emicizumab for the treatment of acquired hemophilia A ...

Our observations suggest emicizumab can facilitate haemostasis for AHA patients and be combined with safer, lower-intensity immunosuppressive therapies to ...

Emicizumab prophylaxis in patients with acquired haemophilia A ...

Standard treatment involves immunosuppressive therapy, which is associated with adverse events and mortality in the frail population of patients ...

Emicizumab versus immunosuppressive therapy for the ...

Acquired hemophilia A (AHA) is an autoimmune bleeding disorder caused by neutralizing antibodies against coagulation factor VIII. Immunosuppressive therapy ...

International recommendations on the diagnosis and treatment of ...

Acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII), ...

Medline ® Abstract for Reference 66 of 'Acquired hemophilia A (and ...

Standard treatment consists of bleeding control with bypassing agents and immunosuppressive therapy. Emicizumab is a bispecific antibody that mimics the ...

Emicizumab for the Treatment of Acquired Hemophilia A

Outcomes could improve with adequate hemostatic prophylaxis in the outpatient setting and reduced immunosuppression. Emicizumab, a FVIII-mimetic ...

Emicizumab: the hemophilia A game-changer - Haematologica

The optimal dosing regimen and duration of treatment with emicizumab for acquired HA remain to be elucidated. An important aspect to consider is ...

Emicizumab in the Treatment of Acquired Haemophilia: A Case Report

Emicizumab is a novel bispecific humanized monoclonal antibody in the treatment of inherited AHA with inhibitors. ... Conventional therapeutic ...

Emicizumab Prophylaxis in Patients Who Have Hemophilia A ...

Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated ...